Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Penelope Jane Hallett, Ph.D.

Title
Institution
Department
Address
Phone

Research
The research activities and funding listed below are automatically derived from NIH ExPORTER and other sources, which might result in incorrect or missing items. Faculty can login to make corrections and additions.
  1. U01NS109463 (HALLETT, PENELOPE JANE) Jan 1, 2020 - Dec 31, 2024
    NIH/NINDS
    Parkinsons disease scalable iPSC autologous cell therapy
    Role: Principal Investigator
  2. R01AG060195 (ISACSON, OLE) Aug 15, 2018 - Apr 30, 2023
    NIH/NIA
    Prevention of complement and immune-mediated Lewy body dementia
    Role: Co-Principal Investigator
  3. R01NS092667 (HALLETT, PENELOPE JANE) Aug 15, 2015 - May 31, 2019
    NIH/NINDS
    Critical analysis of glycosphingolipid pathways in aging and Parkinsons disease
    Role: Principal Investigator

Bibliographic
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
  1. Osborn TM, Hallett PJ, Schumacher JM, Isacson O. Advantages and Recent Developments of Autologous Cell Therapy for Parkinson's Disease Patients. Front Cell Neurosci. 2020; 14:58. PMID: 32317934.
    Citations:    
  2. Huebecker M, Moloney EB, van der Spoel AC, Priestman DA, Isacson O, Hallett PJ, Platt FM. Correction to: Reduced sphingolipid hydrolase activities, substrate accumulation and ganglioside decline in Parkinson's disease. Mol Neurodegener. 2020 Jan 15; 15(1):6. PMID: 31937358.
    Citations:    
  3. Huebecker M, Moloney EB, van der Spoel AC, Priestman DA, Isacson O, Hallett PJ, Platt FM. Reduced sphingolipid hydrolase activities, substrate accumulation and ganglioside decline in Parkinson's disease. Mol Neurodegener. 2019 11 08; 14(1):40. PMID: 31703585.
    Citations:    
  4. Isacson O, Brekk OR, Hallett PJ. Novel Results and Concepts Emerging From Lipid Cell Biology Relevant to Degenerative Brain Aging and Disease. Front Neurol. 2019; 10:1053. PMID: 31649605.
    Citations:    
  5. Korecka JA, Thomas R, Christensen DP, Hinrich AJ, Ferrari EJ, Levy SA, Hastings ML, Hallett PJ, Isacson O. Mitochondrial clearance and maturation of autophagosomes are compromised in LRRK2 G2019S familial Parkinson's disease patient fibroblasts. Hum Mol Genet. 2019 10 01; 28(19):3232-3243. PMID: 31261377.
    Citations:    
  6. Hallett PJ, Engelender S, Isacson O. Lipid and immune abnormalities causing age-dependent neurodegeneration and Parkinson's disease. J Neuroinflammation. 2019 Jul 22; 16(1):153. PMID: 31331333.
    Citations:    
  7. Korecka JA, Talbot S, Osborn TM, de Leeuw SM, Levy SA, Ferrari EJ, Moskites A, Atkinson E, Jodelka FM, Hinrich AJ, Hastings ML, Woolf CJ, Hallett PJ, Isacson O. Neurite Collapse and Altered ER Ca2+ Control in Human Parkinson Disease Patient iPSC-Derived Neurons with LRRK2 G2019S Mutation. Stem Cell Reports. 2019 01 08; 12(1):29-41. PMID: 30595548.
    Citations:    Fields:    
  8. Brekk OR, Moskites A, Isacson O, Hallett PJ. Lipid-dependent deposition of alpha-synuclein and Tau on neuronal Secretogranin II-positive vesicular membranes with age. Sci Rep. 2018 10 12; 8(1):15207. PMID: 30315256.
    Citations:    Fields:    
  9. Moloney EB, Moskites A, Ferrari EJ, Isacson O, Hallett PJ. The glycoprotein GPNMB is selectively elevated in the substantia nigra of Parkinson's disease patients and increases after lysosomal stress. Neurobiol Dis. 2018 12; 120:1-11. PMID: 30149180.
    Citations: 1     Fields:    
  10. Hallett PJ, Huebecker M, Brekk OR, Moloney EB, Rocha EM, Priestman DA, Platt FM, Isacson O. Glycosphingolipid levels and glucocerebrosidase activity are altered in normal aging of the mouse brain. Neurobiol Aging. 2018 07; 67:189-200. PMID: 29735433.
    Citations: 1     Fields:    Translation:AnimalsCells
  11. Osborn T, Hallett PJ. Seq-ing Markers of Midbrain Dopamine Neurons. Cell Stem Cell. 2017 01 05; 20(1):11-12. PMID: 28061349.
    Citations:    Fields:    Translation:HumansCells
  12. Rocha EM, Smith GA, Park E, Cao H, Brown E, Hayes MA, Beagan J, McLean JR, Izen SC, Perez-Torres E, Hallett PJ, Isacson O. Glucocerebrosidase gene therapy prevents a-synucleinopathy of midbrain dopamine neurons. Neurobiol Dis. 2015 Oct; 82:495-503. PMID: 26392287.
    Citations: 20     Fields:    Translation:HumansAnimalsCells
  13. Smith GA, Jansson J, Rocha EM, Osborn T, Hallett PJ, Isacson O. Fibroblast Biomarkers of Sporadic Parkinson's Disease and LRRK2 Kinase Inhibition. Mol Neurobiol. 2016 10; 53(8):5161-77. PMID: 26399642.
    Citations: 5     Fields:    Translation:HumansCells
  14. Rocha EM, Smith GA, Park E, Cao H, Graham AR, Brown E, McLean JR, Hayes MA, Beagan J, Izen SC, Perez-Torres E, Hallett PJ, Isacson O. Sustained Systemic Glucocerebrosidase Inhibition Induces Brain a-Synuclein Aggregation, Microglia and Complement C1q Activation in Mice. Antioxid Redox Signal. 2015 Aug 20; 23(6):550-64. PMID: 26094487.
    Citations: 9     Fields:    Translation:AnimalsCells
  15. Smith GA, Rocha EM, Rooney T, Barneoud P, McLean JR, Beagan J, Osborn T, Coimbra M, Luo Y, Hallett PJ, Isacson O. A Nurr1 agonist causes neuroprotection in a Parkinson's disease lesion model primed with the toll-like receptor 3 dsRNA inflammatory stimulant poly(I:C). PLoS One. 2015; 10(3):e0121072. PMID: 25815475.
    Citations: 11     Fields:    Translation:AnimalsCells
  16. Hallett PJ, Deleidi M, Astradsson A, Smith GA, Cooper O, Osborn TM, Sundberg M, Moore MA, Perez-Torres E, Brownell AL, Schumacher JM, Spealman RD, Isacson O. Successful function of autologous iPSC-derived dopamine neurons following transplantation in a non-human primate model of Parkinson's disease. Cell Stem Cell. 2015 Mar 05; 16(3):269-74. PMID: 25732245.
    Citations: 53     Fields:    Translation:HumansAnimalsCells
  17. Rocha EM, Smith GA, Park E, Cao H, Brown E, Hallett P, Isacson O. Progressive decline of glucocerebrosidase in aging and Parkinson's disease. Ann Clin Transl Neurol. 2015 Apr; 2(4):433-8. PMID: 25909088.
    Citations: 22     
  18. Hallett PJ, Cooper O, Sadi D, Robertson H, Mendez I, Isacson O. Long-term health of dopaminergic neuron transplants in Parkinson's disease patients. Cell Rep. 2014 Jun 26; 7(6):1755-61. PMID: 24910427.
    Citations: 32     Fields:    Translation:HumansCells
  19. McLean JR, Smith GA, Rocha EM, Osborn TM, Dib S, Hayes MA, Beagan JA, Brown TB, Lawson TF, Hallett PJ, Robertson J, Isacson O. ALS-associated peripherin spliced transcripts form distinct protein inclusions that are neuroprotective against oxidative stress. Exp Neurol. 2014 Nov; 261:217-29. PMID: 24907400.
    Citations: 2     Fields:    Translation:HumansCells
  20. McLean JR, Smith GA, Rocha EM, Hayes MA, Beagan JA, Hallett PJ, Isacson O. Widespread neuron-specific transgene expression in brain and spinal cord following synapsin promoter-driven AAV9 neonatal intracerebroventricular injection. Neurosci Lett. 2014 Jul 25; 576:73-8. PMID: 24882721.
    Citations: 20     Fields:    Translation:HumansAnimalsCells
  21. Smith GA, Rocha EM, McLean JR, Hayes MA, Izen SC, Isacson O, Hallett PJ. Progressive axonal transport and synaptic protein changes correlate with behavioral and neuropathological abnormalities in the heterozygous Q175 KI mouse model of Huntington's disease. Hum Mol Genet. 2014 Sep 01; 23(17):4510-27. PMID: 24728190.
    Citations: 19     Fields:    Translation:AnimalsCells
  22. Davies SE, Hallett PJ, Moens T, Smith G, Mangano E, Kim HT, Goldberg AL, Liu JL, Isacson O, Tofaris GK. Enhanced ubiquitin-dependent degradation by Nedd4 protects against a-synuclein accumulation and toxicity in animal models of Parkinson's disease. Neurobiol Dis. 2014 Apr; 64:79-87. PMID: 24388974.
    Citations: 11     Fields:    Translation:HumansAnimalsCells
  23. Sundberg M, Bogetofte H, Lawson T, Jansson J, Smith G, Astradsson A, Moore M, Osborn T, Cooper O, Spealman R, Hallett P, Isacson O. Improved cell therapy protocols for Parkinson's disease based on differentiation efficiency and safety of hESC-, hiPSC-, and non-human primate iPSC-derived dopaminergic neurons. Stem Cells. 2013 Aug; 31(8):1548-62. PMID: 23666606.
    Citations: 49     Fields:    Translation:HumansAnimalsCells
  24. Hallett PJ, McLean JR, Kartunen A, Langston JW, Isacson O. a-Synuclein overexpressing transgenic mice show internal organ pathology and autonomic deficits. Neurobiol Dis. 2012 Aug; 47(2):258-67. PMID: 22549133.
    Citations: 20     Fields:    Translation:HumansAnimals
  25. McLean JR, Hallett PJ, Cooper O, Stanley M, Isacson O. Transcript expression levels of full-length alpha-synuclein and its three alternatively spliced variants in Parkinson's disease brain regions and in a transgenic mouse model of alpha-synuclein overexpression. Mol Cell Neurosci. 2012 Feb; 49(2):230-9. PMID: 22155155.
    Citations: 14     Fields:    Translation:HumansAnimalsCells
  26. Deleidi M, Hargus G, Hallett P, Osborn T, Isacson O. Development of histocompatible primate-induced pluripotent stem cells for neural transplantation. Stem Cells. 2011 Jul; 29(7):1052-63. PMID: 21608081.
    Citations: 22     Fields:    Translation:HumansAnimalsCells
  27. Deleidi M, Hallett PJ, Koprich JB, Chung CY, Isacson O. The Toll-like receptor-3 agonist polyinosinic:polycytidylic acid triggers nigrostriatal dopaminergic degeneration. J Neurosci. 2010 Dec 01; 30(48):16091-101. PMID: 21123556.
    Citations: 28     Fields:    Translation:Animals
  28. Hargus G, Cooper O, Deleidi M, Levy A, Lee K, Marlow E, Yow A, Soldner F, Hockemeyer D, Hallett PJ, Osborn T, Jaenisch R, Isacson O. Differentiated Parkinson patient-derived induced pluripotent stem cells grow in the adult rodent brain and reduce motor asymmetry in Parkinsonian rats. Proc Natl Acad Sci U S A. 2010 Sep 07; 107(36):15921-6. PMID: 20798034.
    Citations: 141     Fields:    Translation:HumansAnimalsCells
  29. Silverdale MA, Kobylecki C, Hallett PJ, Li Q, Dunah AW, Ravenscroft P, Bezard E, Brotchie JM. Synaptic recruitment of AMPA glutamate receptor subunits in levodopa-induced dyskinesia in the MPTP-lesioned nonhuman primate. Synapse. 2010 Feb; 64(2):177-80. PMID: 19852073.
    Citations: 16     Fields:    Translation:AnimalsCells
  30. Chung CY, Koprich JB, Hallett PJ, Isacson O. Functional enhancement and protection of dopaminergic terminals by RAB3B overexpression. Proc Natl Acad Sci U S A. 2009 Dec 29; 106(52):22474-9. PMID: 20007772.
    Citations: 11     Fields:    Translation:HumansAnimalsCells
  31. Hallett PJ, Cooper O, Isacson O. No evidence for disease-like processes in fetal transplants. Proc Natl Acad Sci U S A. 2009 Sep 15; 106(37):E104; author reply E105. PMID: 19805203.
    Citations: 1     Fields:    Translation:HumansCells
  32. Astradsson A, Jenkins BG, Choi JK, Hallett PJ, Levesque MA, McDowell JS, Brownell AL, Spealman RD, Isacson O. The blood-brain barrier is intact after levodopa-induced dyskinesias in parkinsonian primates--evidence from in vivo neuroimaging studies. Neurobiol Dis. 2009 Sep; 35(3):348-51. PMID: 19501164.
    Citations: 13     Fields:    Translation:Animals
  33. Zhang J, Xu TX, Hallett PJ, Watanabe M, Grant SG, Isacson O, Yao WD. PSD-95 uncouples dopamine-glutamate interaction in the D1/PSD-95/NMDA receptor complex. J Neurosci. 2009 Mar 04; 29(9):2948-60. PMID: 19261890.
    Citations: 24     Fields:    Translation:HumansAnimalsCells
  34. Spoelgen R, Adams KW, Koker M, Thomas AV, Andersen OM, Hallett PJ, Bercury KK, Joyner DF, Deng M, Stoothoff WH, Strickland DK, Willnow TE, Hyman BT. Interaction of the apolipoprotein E receptors low density lipoprotein receptor-related protein and sorLA/LR11. Neuroscience. 2009 Feb 18; 158(4):1460-8. PMID: 19047013.
    Citations: 4     Fields:    Translation:HumansAnimalsCells
  35. Vinuela A, Hallett PJ, Reske-Nielsen C, Patterson M, Sotnikova TD, Caron MG, Gainetdinov RR, Isacson O. Implanted reuptake-deficient or wild-type dopaminergic neurons improve ON L-dopa dyskinesias without OFF-dyskinesias in a rat model of Parkinson's disease. Brain. 2008 Dec; 131(Pt 12):3361-79. PMID: 18988638.
    Citations: 11     Fields:    Translation:AnimalsCells
  36. Nicholas AP, Lubin FD, Hallett PJ, Vattem P, Ravenscroft P, Bezard E, Zhou S, Fox SH, Brotchie JM, Sweatt JD, Standaert DG. Striatal histone modifications in models of levodopa-induced dyskinesia. J Neurochem. 2008 Jul; 106(1):486-94. PMID: 18410512.
    Citations: 15     Fields:    Translation:AnimalsCells
  37. Mendez I, Viñuela A, Astradsson A, Mukhida K, Hallett P, Robertson H, Tierney T, Holness R, Dagher A, Trojanowski JQ, Isacson O. Dopamine neurons implanted into people with Parkinson's disease survive without pathology for 14 years. Nat Med. 2008 May; 14(5):507-9. PMID: 18391961.
    Citations: 113     Fields:    Translation:HumansCells
  38. Hallett PJ, Collins TL, Standaert DG, Dunah AW. Biochemical fractionation of brain tissue for studies of receptor distribution and trafficking. Curr Protoc Neurosci. 2008 Jan; Chapter 1:Unit 1.16. PMID: 18428670.
    Citations: 39     Fields:    Translation:AnimalsCells
  39. Zhang J, Vinuela A, Neely MH, Hallett PJ, Grant SG, Miller GM, Isacson O, Caron MG, Yao WD. Inhibition of the dopamine D1 receptor signaling by PSD-95. J Biol Chem. 2007 May 25; 282(21):15778-89. PMID: 17369255.
    Citations: 39     Fields:    Translation:HumansAnimalsCells
  40. Hallett PJ, Brotchie JM. Striatal delta opioid receptor binding in experimental models of Parkinson's disease and dyskinesia. Mov Disord. 2007 Jan; 22(1):28-40. PMID: 17089424.
    Citations: 2     Fields:    Translation:Animals
  41. Hallett PJ, Spoelgen R, Hyman BT, Standaert DG, Dunah AW. Dopamine D1 activation potentiates striatal NMDA receptors by tyrosine phosphorylation-dependent subunit trafficking. J Neurosci. 2006 Apr 26; 26(17):4690-700. PMID: 16641250.
    Citations: 79     Fields:    Translation:AnimalsCells
  42. Hallett PJ, Dunah AW, Ravenscroft P, Zhou S, Bezard E, Crossman AR, Brotchie JM, Standaert DG. Alterations of striatal NMDA receptor subunits associated with the development of dyskinesia in the MPTP-lesioned primate model of Parkinson's disease. Neuropharmacology. 2005 Mar; 48(4):503-16. PMID: 15755478.
    Citations: 39     Fields:    Translation:Animals
  43. Hallett PJ, Standaert DG. Rationale for and use of NMDA receptor antagonists in Parkinson's disease. Pharmacol Ther. 2004 May; 102(2):155-74. PMID: 15163596.
    Citations: 67     Fields:    Translation:HumansAnimals
  44. Hallett PJ Brotchie JM. IBAGS VII Adv Behav Biol. Abnormalities of NMDA receptor-mediated transmission in Parkinson’s disease. 2002; 52:243-53.
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: HMS/HSDM faculty should contact feedbackcatalyst.harvard.edu. For faculty or fellow appointment updates and changes, please ask your appointing department to contact HMS. For fellow personal and demographic information, contact HMS Human Resources at human_resourceshms.harvard.edu. For faculty personal and demographic information, contact HMS Office for Faculty Affairs at facappthms.harvard.edu.
Hallett's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts (229)
Explore
_
Co-Authors (16)
Explore
_
Similar People (60)
Explore
_
Same Department 
Explore
_
Physical Neighbors
_
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.